Amgen's Cholesterol Drug Patents Are Valid, Jury Says

Law360 (February 25, 2019, 10:43 PM EST) -- Patents related to Amgen Inc.'s cholesterol-lowering drug Repatha survived a challenge by rival pharmaceutical company Sanofi when a Delaware federal jury found largely in Amgen's favor Monday.

The jury upheld three of the five claims Amgen had asserted regarding its Repatha patents, which the California-based drugmaker had claimed were infringed by a competing drug, Praluent, made by Regeneron Pharmaceuticals, a subsidiary of France's Sanofi, according to news releases from the companies.

"Today's decision protects intellectual property, which is essential to innovators who are bringing forward new medicines for patients with serious diseases," Amgen CEO Robert A. Bradway said in a statement....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS